Burning Rock Biotech Limited Sponsored ADR $BNR is Crcm LP’s 7th Largest Position

Crcm LP lifted its holdings in shares of Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) by 121.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 491,426 shares of the company’s stock after purchasing an additional 269,851 shares during the quarter. Burning Rock Biotech comprises approximately 3.3% of Crcm LP’s investment portfolio, making the stock its 7th biggest position. Crcm LP owned 4.57% of Burning Rock Biotech worth $9,902,000 as of its most recent SEC filing.

Separately, Prospera Financial Services Inc purchased a new position in shares of Burning Rock Biotech during the 3rd quarter worth $214,000. 30.03% of the stock is currently owned by institutional investors and hedge funds.

Burning Rock Biotech Stock Performance

Shares of Burning Rock Biotech stock opened at $8.59 on Friday. The business has a 50-day moving average of $15.44 and a 200 day moving average of $21.12. Burning Rock Biotech Limited Sponsored ADR has a 12 month low of $3.06 and a 12 month high of $41.72. The stock has a market capitalization of $90.37 million, a price-to-earnings ratio of -10.48 and a beta of 1.32. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.05 and a quick ratio of 2.79.

Burning Rock Biotech (NASDAQ:BNR) last announced its earnings results on Tuesday, June 9th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($2.29) by $2.09. The company had revenue of $15.66 million during the quarter, compared to analysts’ expectations of $19.21 million. Burning Rock Biotech had a negative return on equity of 10.98% and a negative net margin of 11.57%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Wall Street Zen cut Burning Rock Biotech from a “buy” rating to a “hold” rating in a report on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Burning Rock Biotech in a report on Monday, April 20th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Burning Rock Biotech currently has an average rating of “Sell”.

Insider Transactions at Burning Rock Biotech

In related news, Director Yusheng Han purchased 314,870 shares of Burning Rock Biotech stock in a transaction on Tuesday, March 31st. The shares were bought at an average price of $17.36 per share, with a total value of $5,466,143.20. Following the transaction, the director directly owned 17,672,676 shares of the company’s stock, valued at approximately $306,797,655.36. This trade represents a 1.81% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 30.30% of the stock is owned by corporate insiders.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.